Exelead is a CDMO dedicated to the development and commercialization of therapeutics to treat life-threatening diseases for small populations. The company specializes in liposomal and PEGylated formulations for sterile drug products, offering rare dedication to the customer who needs a partner.
Exelead’s development capabilities can be utilized to improve drug delivery and drug product characterization. At their Indianapolis, Indiana manufacturing facility, the Exelead team produces proprietary parenteral pharmaceuticals for oncology and enzyme replacement treatment, as well as for the treatment of numerous infectious diseases.
Exelead staff is a balance of chemists, chemical engineers, microbiologists and pharmaceutical manufacturing experts. Senior Exelead management is comprised of seasoned executives from the pharmaceutical and biotechnology industries. The company is a wholly owned subsidiary of Essetifin S.p.A. (Rome, Italy) and is led by John Rigg, CEO.
Posted Date: 7/3/2018
This record has been viewed 4049 times.